Biogen: Renal Insufficiency, Chronic trials
The registry lists 10 Renal Insufficiency, Chronic studies with Biogen as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 3Phase 2 5Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)CompletedNCT04702997Phase 2Results posted
- An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)TerminatedNCT03749447Phase 3Results posted
- A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXCompletedNCT03366337Phase 2Results posted
- A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes MellitusWithdrawnNCT01655186Phase 2
- Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 DiabetesWithdrawnNCT01551446Phase 1
- Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 DiabetesTerminatedNCT01549769Phase 1
- A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 DiabetesTerminatedNCT01500798Phase 1
- Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 DiabetesTerminatedNCT01351675Phase 3
- Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedNCT01053936Phase 2
- Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedNCT00811889Phase 2